← Back to patent-cliff list
Colistimethate E2 sodium (Jiangsu Chia Tai-Tianqing Pharmaceutical)
Tier C — Watch / tradeColistimethate E2 sodium (Jiangsu Chia Tai-Tianqing Pharmaceutical)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Ventilator-associated pneumonia, Hospital-acquired pneumonia, Bacterial infection
Regional status
US
-
EU
-
China
Phase II
2026-07-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Colistimethate E2 sodium (Jiangsu Chia Tai-Tianqing Pharmaceutical)?
Approved indications include: Ventilator-associated pneumonia, Hospital-acquired pneumonia, Bacterial infection.
When does the Colistimethate E2 sodium (Jiangsu Chia Tai-Tianqing Pharmaceutical) patent expire?
No public expiry year is available for Colistimethate E2 sodium (Jiangsu Chia Tai-Tianqing Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Colistimethate E2 sodium (Jiangsu Chia Tai-Tianqing Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29